Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS	22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:43:56 ON 13 APR 2009

=> File .Gerry2MBCE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'MEDLINE' ENTERED AT 15:44:19 ON 13 APR 2009

FILE 'BIOSIS' ENTERED AT 15:44:19 ON 13 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:44:19 ON 13 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:44:19 ON 13 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> S (therapeutical? amount) (S) G-CSF (S) mg AND pd<=20031104
   2 FILES SEARCHED...
L1           0 (THERAPEUTICAL? AMOUNT) (S) G-CSF (S) MG AND PD<=20031104

=> S (therapeutical? amount) (S) G-CSF AND pd<=20031104
   2 FILES SEARCHED...
L2           0 (THERAPEUTICAL? AMOUNT) (S) G-CSF AND PD<=20031104

=> S (therapeutical? (3A) amount) (S) G-CSF AND pd<=20031104
   2 FILES SEARCHED...
L3           5 (THERAPEUTICAL? (3A) AMOUNT) (S) G-CSF AND PD<=20031104

=> Dup rem L3
PROCESSING COMPLETED FOR L3
L4            3 DUP REM L3 (2 DUPLICATES REMOVED)
                ANSWER '1' FROM FILE MEDLINE
                ANSWERS '2-3' FROM FILE CAPLUS

=> D Ibib abs L4 1-3

L4   ANSWER 1 OF 3     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:   1999426533     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 10498245
TITLE:              Persistent, therapeutically relevant levels of human
                    granulocyte colony-stimulating factor in mice after
                    systemic delivery of adeno-associated virus vectors.
AUTHOR:             Koeberl D D; Bonham L; Halbert C L; Allen J M; Birkebak T;
                    Miller A D
```

CORPORATE SOURCE: Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
CONTRACT NUMBER: DK47754 (United States NIDDK NIH HHS)
HL3644 (United States NHLBI NIH HHS)
SOURCE: Human gene therapy, (1999 Sep 1) Vol. 10, No. 13, pp. 2133-40.
Journal code: 9008950. ISSN: 1043-0342.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199910
ENTRY DATE: Entered STN: 11 Jan 2000
Last Updated on STN: 11 Jan 2000
Entered Medline: 27 Oct 1999

AB Adeno-associated virus (AAV) vectors have been shown to preferentially transduce hepatocytes after systemic administration in adult mice and to provide long-term expression of introduced genes. One application of this technology would be for the production of granulocyte colony-stimulating factor (G-CSF), which increases mature neutrophil numbers in humans and in animals, and has therapeutic effects in disorders featuring chronic neutropenia, including cyclic, severe congenital, and idiopathic neutropenia, and glycogen storage disease type Ib. We have treated mice by tail vein injection of AAV vectors encoding human G-CSF, and have detected high G-CSF levels and marked elevation of neutrophil counts for at least 5 months. A therapeutically relevant amount of G-CSF production was obtained when the liver-specific mouse albumin promoter-enhancer was used to drive G -CSF expression. In mice receiving higher amounts of vector, plasma levels of human G-CSF gradually increased over 3 weeks to high concentrations, whereas for lower amounts human G-CSF remained at initial, low levels. The previously observed effect of gamma irradiation, to increase AAV transduction rates, was diminished when large amounts of vector were used. Absolute neutrophil counts increased 10- to 50-fold for the period of observation to levels that would be therapeutic in the treatment of cyclic neutropenia. In conclusion, gene therapy with AAV vectors synthesizing G-CSF shows promise for the treatment of disorders featuring neutropenia.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:394304 CAPLUS
DOCUMENT NUMBER: 127:4088
ORIGINAL REFERENCE NO.: 127:951a,954a
TITLE: Novel uses of mammalian CTLA-8 and related reagents
INVENTOR(S): Banchereau, Jacques; Djossou, Odille; Flores-Romo, Leopoldo; Fossiez, Francois; Golstein, Pierre; Krishna, Mala; Lebecque, Serge J. E.; Murray, Richard
PATENT ASSIGNEE(S): Schering Corporation, USA; Institut National De La Sante Et De La Recherche Medicale
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715320	A1	19970501	WO 1996-US16315	19961023 <--

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL,

IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2235951	A1	19970501	CA 1996-2235951	19961023	<--
CA 2235951	C	20030401			
AU 9674399	A	19970515	AU 1996-74399	19961023	<--
EP 862454	A1	19980909	EP 1996-936385	19961023	<--
EP 862454	B1	20020828			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO					
JP 10512293	T	19981124	JP 1997-516631	19961023	<--
JP 3253633	B2	20020204			
JP 2002145799	A	20020522	JP 2001-275810	19961023	<--
AT 222768	T	20020915	AT 1996-936385	19961023	<--
PT 862454	T	20021129	PT 1996-936385	19961023	<--
ES 2181915	T3	20030301	ES 1996-936385	19961023	<--
US 6063372	A	20000516	US 1996-736299	19961024	<--
HK 1015692	A1	20021129	HK 1999-100811	19990227	<--

PRIORITY APPLN. INFO.:	US 1995-5909P	P	19951027
	US 1995-569742	A	19951208
	JP 1997-516631	A3	19961023
	WO 1996-US16315	W	19961023

AB Compns. and method for using CTLA-8 to treat an abnormal physiol. condition in an individual, e.g. microbial infection, sepsis and septic shock, or abnormal hematopoiesis. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or in combination with other therapeutic reagents; or a CTLA-8 antagonists (e.g. interleukin 6 or G-CSF).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1992:620119 CAPLUS
DOCUMENT NUMBER:	117:220119
ORIGINAL REFERENCE NO.:	117:37879a,37882a
TITLE:	Pulmonary administration of granulocyte colony stimulating factor
INVENTOR(S):	Platz, Robert M.; Winters, Mark A.; Pitt, Colin G.
PATENT ASSIGNEE(S):	Amgen Inc., USA
SOURCE:	Eur. Pat. Appl., 15 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 505123	A1	19920923	EP 1992-302239	19920316	<--
EP 505123	B1	19970108			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE					
WO 9216192	A1	19921001	WO 1992-US2126	19920313	<--
W: AU, CA, FI, JP, KR, NO					
AU 9217476	A	19921021	AU 1992-17476	19920313	<--
AU 643141	B2	19931104			
JP 05507944	T	19931111	JP 1992-509349	19920313	<--
JP 3507486	B2	20040315			
CA 2082951	C	19991221	CA 1992-2082951	19920313	<--
CN 1066192	A	19921118	CN 1992-102497	19920314	<--
IL 101235	A	19981030	IL 1992-101235	19920315	<--

ZA 9201915	A	19930428	ZA 1992-1915	19920316	<--
AT 147270	T	19970115	AT 1992-302239	19920316	<--
ES 2097866	T3	19970416	ES 1992-302239	19920316	<--
FI 106433	B1	20010215	FI 1992-5163	19921113	<--
NO 9204413	A	19930114	NO 1992-4413	19921116	<--
NO 303716	B1	19980824			

PRIORITY APPLN. INFO.: US 1991-669792 A 19910315
WO 1992-US2126 A 19920313

AB Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amts. by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration results in significant elevation of the neutrophil level that compares favorably with delivery by s.c. injection. G-CSF can be administered in this manner to medically treat neutropenia, or combat or prevent infections. An aerosol contained rh-G-CSF 5 mg/mL. The inhalation exposure to the aerosol in hamsters produced a neutrophil response of 9910 as compared to 10935 μg/μL for 50μg/kg s.c. injection.

=> Log Off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:49:25 ON 13 APR 2009